The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT02620046




Registration number
NCT02620046
Ethics application status
Date submitted
19/11/2015
Date registered
2/12/2015
Date last updated
8/05/2024

Titles & IDs
Public title
A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
Scientific title
A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease
Secondary ID [1] 0 0
U1111-1168-0921
Secondary ID [2] 0 0
MLN0002SC-3030
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Colitis, Ulcerative 0 0
Crohn's Disease 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Inflammatory bowel disease
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Oral and Gastrointestinal 0 0 0 0
Crohn's disease
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Vedolizumab SC

Experimental: Group A: Vedolizumab SC 108 mg Q2W - Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who:
Completed the Maintenance Period (Week 52), or
Were not randomized into Maintenance Period and achieved response at Week 14 after having received a third vedolizumab IV infusion at Week 6.

Experimental: Group B: Vedolizumab SC 108 mg QW - Participants from studies MLN0002SC-3027 and MLN0002SC-3031 who withdrew early from the Maintenance Period due to treatment failure.
•Participants from current study who experience treatment failure while on study.


Treatment: Drugs: Vedolizumab SC
Vedolizumab SC 108 mg injection

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment
Timepoint [1] 0 0
From start of study medication through 18 weeks after the last dose
Secondary outcome [1] 0 0
Number of Adverse Events of Special Interest (AESIs) Adjusted by Duration of Participant's Exposure to Long-term Vedolizumab Treatment
Timepoint [1] 0 0
From start of study medication through 18 weeks after the last dose
Secondary outcome [2] 0 0
Percentage of Participants with Ulcerative Colitis Achieving Partial Mayo Scoring Clinical Response
Timepoint [2] 0 0
From Week 0 (Day 1) up to availability of vedolizumab SC, withdrawal by participant, or study closure, Up to 7 years
Secondary outcome [3] 0 0
Percentage of Participants with Crohn's Disease Achieving Clinical Response
Timepoint [3] 0 0
From Week 0 (Day 1) up to availability of vedolizumab SC, withdrawal by participant, or study closure, Up to 7 years
Secondary outcome [4] 0 0
Percentage of Participants with Ulcerative Colitis Achieving Clinical Remission
Timepoint [4] 0 0
From Week 0 (Day 1) up to availability of vedolizumab SC, withdrawal by participant, or study closure, up to 7 years
Secondary outcome [5] 0 0
Percentage of Participants with Crohn's Disease (CD) Achieving Clinical Remission
Timepoint [5] 0 0
From Week 0 (Day 1) up to availability of vedolizumab SC, withdrawal by participant, or study closure, Up to 7 years

Eligibility
Key inclusion criteria
1. Prior participation in Study MLN0002SC-3027 or MLN0002SC-3031, and, in the opinion of
the investigator, tolerated the study drug well. Early withdrawal from Study MLN0002SC-3027
or MLN0002SC-3031 must have been due to treatment failure during the Maintenance Period.
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Surgical intervention for IBD during or after participation in Study MLN0002SC-3027 or
MLN0002SC-3031, or at any time during this study.

2. Chronic or severe infection, or, any new, unstable, or uncontrolled cardiovascular,
pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological,
coagulation, immunological, endocrine/metabolic, neurologic, oncologic, or other
medical disorder developed during or after participation in a prior vedolizumab study
that, in the opinion of the investigator, would confound the study results or
compromise participant safety.

3. Withdrawal from Study MLN0002SC-3027 or MLN0002SC-3031 due to a study-drug related
adverse event (AE).

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Concord Repatriation General Hospital - Concord
Recruitment hospital [2] 0 0
Nepean Hospital - Kingswood
Recruitment hospital [3] 0 0
Mater Hospital Brisbane - South Brisbane
Recruitment hospital [4] 0 0
Princess Alexandra Hospital - Woolloongabba
Recruitment hospital [5] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [6] 0 0
Tennyson Centre Day Hospital - Kurralta Park
Recruitment hospital [7] 0 0
Ballarat Base Hospital - Ballarat
Recruitment hospital [8] 0 0
Monash Medical Centre Clayton - Bentleigh East
Recruitment hospital [9] 0 0
St Vincent's Hospital Melbourne - Fitzroy
Recruitment hospital [10] 0 0
St Frances Xavier Cabrini Hospital - Malvern
Recruitment hospital [11] 0 0
Royal Melbourne Hospital - Melbourne
Recruitment hospital [12] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [13] 0 0
Fiona Stanley Hospital - Murdoch
Recruitment hospital [14] 0 0
St John of God Subiaco Hospital - Subiaco
Recruitment postcode(s) [1] 0 0
2139 - Concord
Recruitment postcode(s) [2] 0 0
2747 - Kingswood
Recruitment postcode(s) [3] 0 0
4101 - South Brisbane
Recruitment postcode(s) [4] 0 0
4102 - Woolloongabba
Recruitment postcode(s) [5] 0 0
5000 - Adelaide
Recruitment postcode(s) [6] 0 0
5037 - Kurralta Park
Recruitment postcode(s) [7] 0 0
3350 - Ballarat
Recruitment postcode(s) [8] 0 0
3165 - Bentleigh East
Recruitment postcode(s) [9] 0 0
3065 - Fitzroy
Recruitment postcode(s) [10] 0 0
3144 - Malvern
Recruitment postcode(s) [11] 0 0
3000 - Melbourne
Recruitment postcode(s) [12] 0 0
3181 - Melbourne
Recruitment postcode(s) [13] 0 0
6150 - Murdoch
Recruitment postcode(s) [14] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
Arkansas
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Kansas
Country [10] 0 0
United States of America
State/province [10] 0 0
Kentucky
Country [11] 0 0
United States of America
State/province [11] 0 0
Louisiana
Country [12] 0 0
United States of America
State/province [12] 0 0
Maryland
Country [13] 0 0
United States of America
State/province [13] 0 0
Michigan
Country [14] 0 0
United States of America
State/province [14] 0 0
Minnesota
Country [15] 0 0
United States of America
State/province [15] 0 0
Mississippi
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
New Jersey
Country [18] 0 0
United States of America
State/province [18] 0 0
New York
Country [19] 0 0
United States of America
State/province [19] 0 0
North Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Ohio
Country [21] 0 0
United States of America
State/province [21] 0 0
Oklahoma
Country [22] 0 0
United States of America
State/province [22] 0 0
Pennsylvania
Country [23] 0 0
United States of America
State/province [23] 0 0
South Carolina
Country [24] 0 0
United States of America
State/province [24] 0 0
Tennessee
Country [25] 0 0
United States of America
State/province [25] 0 0
Texas
Country [26] 0 0
United States of America
State/province [26] 0 0
Virginia
Country [27] 0 0
United States of America
State/province [27] 0 0
Washington
Country [28] 0 0
United States of America
State/province [28] 0 0
Wisconsin
Country [29] 0 0
Argentina
State/province [29] 0 0
Buenos Aires
Country [30] 0 0
Argentina
State/province [30] 0 0
Ciudad Autonoma Buenos Aires
Country [31] 0 0
Belgium
State/province [31] 0 0
Bonheiden
Country [32] 0 0
Belgium
State/province [32] 0 0
Brugge
Country [33] 0 0
Belgium
State/province [33] 0 0
Gent
Country [34] 0 0
Belgium
State/province [34] 0 0
Kortrijk
Country [35] 0 0
Belgium
State/province [35] 0 0
Merksem
Country [36] 0 0
Belgium
State/province [36] 0 0
Ottignies
Country [37] 0 0
Belgium
State/province [37] 0 0
Roeselare
Country [38] 0 0
Bosnia and Herzegovina
State/province [38] 0 0
Banja Luka
Country [39] 0 0
Bosnia and Herzegovina
State/province [39] 0 0
Mostar
Country [40] 0 0
Brazil
State/province [40] 0 0
Goias
Country [41] 0 0
Brazil
State/province [41] 0 0
Rio Do Janeiro
Country [42] 0 0
Brazil
State/province [42] 0 0
Rio Grande Do Sul
Country [43] 0 0
Brazil
State/province [43] 0 0
Sao Paulo
Country [44] 0 0
Bulgaria
State/province [44] 0 0
Pleven
Country [45] 0 0
Bulgaria
State/province [45] 0 0
Silistra
Country [46] 0 0
Bulgaria
State/province [46] 0 0
Sliven
Country [47] 0 0
Bulgaria
State/province [47] 0 0
Sofia
Country [48] 0 0
Bulgaria
State/province [48] 0 0
Stara Zagora
Country [49] 0 0
Canada
State/province [49] 0 0
Alberta
Country [50] 0 0
Canada
State/province [50] 0 0
British Columbia
Country [51] 0 0
Canada
State/province [51] 0 0
Ontario
Country [52] 0 0
Croatia
State/province [52] 0 0
Osijek
Country [53] 0 0
Croatia
State/province [53] 0 0
Rijeka
Country [54] 0 0
Croatia
State/province [54] 0 0
Zagreb
Country [55] 0 0
Czechia
State/province [55] 0 0
Brno
Country [56] 0 0
Czechia
State/province [56] 0 0
Hradec Kralove
Country [57] 0 0
Czechia
State/province [57] 0 0
Plzen
Country [58] 0 0
Czechia
State/province [58] 0 0
Praha 10
Country [59] 0 0
Czechia
State/province [59] 0 0
Praha 3
Country [60] 0 0
Czechia
State/province [60] 0 0
Praha 5
Country [61] 0 0
Czechia
State/province [61] 0 0
Tabor
Country [62] 0 0
Denmark
State/province [62] 0 0
Odense C
Country [63] 0 0
Denmark
State/province [63] 0 0
Silkeborg
Country [64] 0 0
Estonia
State/province [64] 0 0
Tallinn
Country [65] 0 0
Estonia
State/province [65] 0 0
Tartu
Country [66] 0 0
Germany
State/province [66] 0 0
Bayern
Country [67] 0 0
Germany
State/province [67] 0 0
Hessen
Country [68] 0 0
Germany
State/province [68] 0 0
Niedersachsen
Country [69] 0 0
Germany
State/province [69] 0 0
Nordrhein Westfalen
Country [70] 0 0
Germany
State/province [70] 0 0
Rheinland Pfalz
Country [71] 0 0
Germany
State/province [71] 0 0
Sachsen Anhalt
Country [72] 0 0
Germany
State/province [72] 0 0
Sachsen
Country [73] 0 0
Germany
State/province [73] 0 0
Schleswig Holstein
Country [74] 0 0
Germany
State/province [74] 0 0
Berlin
Country [75] 0 0
Hungary
State/province [75] 0 0
Budapest
Country [76] 0 0
Hungary
State/province [76] 0 0
Eger
Country [77] 0 0
Hungary
State/province [77] 0 0
Gyula
Country [78] 0 0
Hungary
State/province [78] 0 0
Kistarcsa
Country [79] 0 0
Hungary
State/province [79] 0 0
Miskolc
Country [80] 0 0
Hungary
State/province [80] 0 0
Mosonmagyarovar
Country [81] 0 0
Hungary
State/province [81] 0 0
Pecs
Country [82] 0 0
Hungary
State/province [82] 0 0
Szekesfehervar
Country [83] 0 0
Hungary
State/province [83] 0 0
Szekszard
Country [84] 0 0
Israel
State/province [84] 0 0
Afula
Country [85] 0 0
Israel
State/province [85] 0 0
Ashkelon
Country [86] 0 0
Israel
State/province [86] 0 0
Beer Sheva
Country [87] 0 0
Israel
State/province [87] 0 0
Haifa
Country [88] 0 0
Israel
State/province [88] 0 0
Holon
Country [89] 0 0
Israel
State/province [89] 0 0
Jerusalem
Country [90] 0 0
Israel
State/province [90] 0 0
Nahariya
Country [91] 0 0
Israel
State/province [91] 0 0
Ramat Gan
Country [92] 0 0
Israel
State/province [92] 0 0
Rechovot
Country [93] 0 0
Israel
State/province [93] 0 0
Tel Aviv
Country [94] 0 0
Italy
State/province [94] 0 0
Foggia
Country [95] 0 0
Italy
State/province [95] 0 0
Milano
Country [96] 0 0
Italy
State/province [96] 0 0
Bologna
Country [97] 0 0
Italy
State/province [97] 0 0
Catania
Country [98] 0 0
Italy
State/province [98] 0 0
Messina
Country [99] 0 0
Italy
State/province [99] 0 0
Modena
Country [100] 0 0
Italy
State/province [100] 0 0
Napoli
Country [101] 0 0
Italy
State/province [101] 0 0
Padova
Country [102] 0 0
Italy
State/province [102] 0 0
Palermo
Country [103] 0 0
Italy
State/province [103] 0 0
Roma
Country [104] 0 0
Japan
State/province [104] 0 0
Aichi-Ken
Country [105] 0 0
Japan
State/province [105] 0 0
Chiba-Ken
Country [106] 0 0
Japan
State/province [106] 0 0
Ehime-Ken
Country [107] 0 0
Japan
State/province [107] 0 0
Fukuoka-Ken
Country [108] 0 0
Japan
State/province [108] 0 0
Hiroshima-Ken
Country [109] 0 0
Japan
State/province [109] 0 0
Hokkaido
Country [110] 0 0
Japan
State/province [110] 0 0
Hyogo-Ken
Country [111] 0 0
Japan
State/province [111] 0 0
Iwate-Ken
Country [112] 0 0
Japan
State/province [112] 0 0
Kagawa-Ken
Country [113] 0 0
Japan
State/province [113] 0 0
Kanagawa-Ken
Country [114] 0 0
Japan
State/province [114] 0 0
Okayama-Ken
Country [115] 0 0
Japan
State/province [115] 0 0
Osaka-Fu
Country [116] 0 0
Japan
State/province [116] 0 0
Saga-Ken
Country [117] 0 0
Japan
State/province [117] 0 0
Shiga-Ken
Country [118] 0 0
Japan
State/province [118] 0 0
Shizuoka-Ken
Country [119] 0 0
Japan
State/province [119] 0 0
Tokyo-To
Country [120] 0 0
Japan
State/province [120] 0 0
Wakayama-Ken
Country [121] 0 0
Korea, Republic of
State/province [121] 0 0
Gyeongsangbuk-do
Country [122] 0 0
Korea, Republic of
State/province [122] 0 0
Daegu
Country [123] 0 0
Korea, Republic of
State/province [123] 0 0
Seoul
Country [124] 0 0
Lithuania
State/province [124] 0 0
Kaunas
Country [125] 0 0
Lithuania
State/province [125] 0 0
Klaipeda
Country [126] 0 0
Lithuania
State/province [126] 0 0
Vilnius
Country [127] 0 0
Mexico
State/province [127] 0 0
Guanajuato
Country [128] 0 0
Mexico
State/province [128] 0 0
Jalisco
Country [129] 0 0
Mexico
State/province [129] 0 0
Nuevo Leon
Country [130] 0 0
Mexico
State/province [130] 0 0
Durango
Country [131] 0 0
Mexico
State/province [131] 0 0
Veracruz
Country [132] 0 0
Netherlands
State/province [132] 0 0
Amsterdam
Country [133] 0 0
Netherlands
State/province [133] 0 0
Dordrecht
Country [134] 0 0
Netherlands
State/province [134] 0 0
Groningen
Country [135] 0 0
Netherlands
State/province [135] 0 0
Maastricht
Country [136] 0 0
Netherlands
State/province [136] 0 0
Rotterdam
Country [137] 0 0
Poland
State/province [137] 0 0
Bialystok
Country [138] 0 0
Poland
State/province [138] 0 0
Bydgoszcz
Country [139] 0 0
Poland
State/province [139] 0 0
Katowice
Country [140] 0 0
Poland
State/province [140] 0 0
Krakow
Country [141] 0 0
Poland
State/province [141] 0 0
Lodz
Country [142] 0 0
Poland
State/province [142] 0 0
Lublin
Country [143] 0 0
Poland
State/province [143] 0 0
Szczecin
Country [144] 0 0
Poland
State/province [144] 0 0
Warszawa
Country [145] 0 0
Poland
State/province [145] 0 0
Wroclaw
Country [146] 0 0
Romania
State/province [146] 0 0
Bucuresti
Country [147] 0 0
Romania
State/province [147] 0 0
Timisoara
Country [148] 0 0
Russian Federation
State/province [148] 0 0
Kazan
Country [149] 0 0
Russian Federation
State/province [149] 0 0
Krasnoyarsk
Country [150] 0 0
Russian Federation
State/province [150] 0 0
Moscow
Country [151] 0 0
Russian Federation
State/province [151] 0 0
Novosibirsk
Country [152] 0 0
Russian Federation
State/province [152] 0 0
Omsk
Country [153] 0 0
Russian Federation
State/province [153] 0 0
Rostov-on-Don
Country [154] 0 0
Russian Federation
State/province [154] 0 0
Saint-Petersburg
Country [155] 0 0
Russian Federation
State/province [155] 0 0
Sestroretsk
Country [156] 0 0
Russian Federation
State/province [156] 0 0
St. Petersburg
Country [157] 0 0
Serbia
State/province [157] 0 0
Belgrade
Country [158] 0 0
Serbia
State/province [158] 0 0
Kragujevac
Country [159] 0 0
Serbia
State/province [159] 0 0
Nis
Country [160] 0 0
Serbia
State/province [160] 0 0
Novi Sad
Country [161] 0 0
Slovakia
State/province [161] 0 0
Banska Bystrica
Country [162] 0 0
Slovakia
State/province [162] 0 0
Bratislava
Country [163] 0 0
Slovakia
State/province [163] 0 0
Kosice
Country [164] 0 0
Slovakia
State/province [164] 0 0
Nitra
Country [165] 0 0
Slovakia
State/province [165] 0 0
Presov
Country [166] 0 0
South Africa
State/province [166] 0 0
Gauteng
Country [167] 0 0
South Africa
State/province [167] 0 0
Western Cape
Country [168] 0 0
Spain
State/province [168] 0 0
Barcelona
Country [169] 0 0
Spain
State/province [169] 0 0
Madrid
Country [170] 0 0
Spain
State/province [170] 0 0
Alicante
Country [171] 0 0
Spain
State/province [171] 0 0
Girona
Country [172] 0 0
Spain
State/province [172] 0 0
Pontevedra
Country [173] 0 0
Sweden
State/province [173] 0 0
Stockholm
Country [174] 0 0
Taiwan
State/province [174] 0 0
Taipei
Country [175] 0 0
Turkey
State/province [175] 0 0
Ankara
Country [176] 0 0
Turkey
State/province [176] 0 0
Istanbul
Country [177] 0 0
Turkey
State/province [177] 0 0
Kocaeli
Country [178] 0 0
Turkey
State/province [178] 0 0
Mersin
Country [179] 0 0
Ukraine
State/province [179] 0 0
Chernivtsi
Country [180] 0 0
Ukraine
State/province [180] 0 0
Dnipro
Country [181] 0 0
Ukraine
State/province [181] 0 0
Ivano-Frankivsk
Country [182] 0 0
Ukraine
State/province [182] 0 0
Kharkiv
Country [183] 0 0
Ukraine
State/province [183] 0 0
Kherson
Country [184] 0 0
Ukraine
State/province [184] 0 0
Kyiv
Country [185] 0 0
Ukraine
State/province [185] 0 0
Lviv
Country [186] 0 0
Ukraine
State/province [186] 0 0
Odesa
Country [187] 0 0
Ukraine
State/province [187] 0 0
Ternopil
Country [188] 0 0
Ukraine
State/province [188] 0 0
Vinnytsia
Country [189] 0 0
Ukraine
State/province [189] 0 0
Zaporizhzhia
Country [190] 0 0
United Kingdom
State/province [190] 0 0
Devon
Country [191] 0 0
United Kingdom
State/province [191] 0 0
Greater London
Country [192] 0 0
United Kingdom
State/province [192] 0 0
Norfolk
Country [193] 0 0
United Kingdom
State/province [193] 0 0
Shropshire
Country [194] 0 0
United Kingdom
State/province [194] 0 0
West Midlands

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Takeda
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous
(also known as Vedolizumab SC) in people with ulcerative colitis and Crohn's disease.
Vedolizumab SC will be given as an injection just under the skin. This type of injection is
called a subcutaneous injection or SC for short. Another aim of the study is to collect
information on whether the participant's condition remains under control or improves during
and after treatment with Vedolizumab SC.

Participants who previously took part in studies MLN0002SC-3027 or MLN0002SC-3031 will be
invited to visit the study clinic. At this visit, the study doctor will check if each
participant can take part in this study.

For those who can take part, participants will receive a subcutaneous injection of
vedolizumab SC either once a week or once every 2 weeks. How often each participant receives
vedolizumab SC will depend on their results from the previous study and on how active their
condition is. Participants might be able to self-inject vedolizumab SC after being trained by
the study doctors. During this study, the dose of vedolizumab SC might be increased for
participants whose condition worsens.

Participants will continue treatment with vedolizumab SC until it is approved in their
particular country, the participant decides to stop treatment, or the sponsor stops the
study. If the sponsor stops the study before vedolizumab SC is approved in all countries, the
sponsor will make sure all affected participants will have access to vedolizumab SC outside
of the study.

After their final dose of vedolizumab SC, participants will visit the clinic 18 weeks later
for a final check-up. Then, the clinic will telephone the participants 6 months after their
final dose of vedolizumab SC to check if they have any health problems.
Trial website
https://clinicaltrials.gov/ct2/show/NCT02620046
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director Clinical Science
Address 0 0
Takeda
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT02620046